anti-egfr

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Anti-EGFR Antibody (1M661) is a Rabbit IgG monoclonal antibody targeting Human EGFR.

Anti-EGFR Antibody (1X807) is a Rabbit IgG monoclonal antibody targeting Human EGFR.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.

Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.

Tomuzotuximab, a fully human glycoengineered IgG1 monoclonal antibody targeting EGFR (Anti-Human EGFR Recombinant Antibody), exhibits anticancer effects [1].

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.

Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.

Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models, and is utilized for research on cancer [1].

Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising the anti-EGFR monoclonal antibody depatuxizumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). This ADC effectively suppresses the growth of xenograft models harboring both mutant EGFRvIII and wild-type EGFR [1].

Laprituximab emtansine (IMGN-289), an immunotoxin targeting HER1, is an EGFR antibody-drug conjugate (ADC) composed of J2898A antibody, DM1 (anti-microtubule agent), and the SMCC thioether linker, utilized in cancer research [1] [2] [3].

Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is a conjugate comprising Cetuximab, an anti-EGFR monoclonal antibody, and IRdye700DX, a near-infrared photosensitizing dye. It is utilized in the study of head and neck cancers [1] [2].

Regn7075 is an innovative first-in-class bispecific antibody (bsAb) designed to restore immune sensitivity in traditionally unresponsive tumors by connecting CD28+ T cells with tumor cells expressing EGFR. It enhances immune response and antitumor immunity. The molecular weight is 145.24 KD.

MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.